Adaptimmune Appoints Leading Immunotherapy Experts from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB). Crystal Mackall, M.D., Professor of Pediatrics and Medicine and Associate Director of the Stanford Cancer Institute, will serve as Chair of the SAB.

The SAB will serve as a strategic resource for Adaptimmune and help to steer the company’s development efforts in the field of immuno-oncology. 

“Adaptimmune is the clear leader in the TCR T-cell therapy space, and I’m very pleased to join their scientific advisory board as Chair at this important time in their evolution,” said Dr. Mackall.

“Our inaugural scientific advisory board members bring a wealth of experience in areas including gene therapy, immunotherapy and oncology, and we are honored to have such a prestigious group of advisors,” said James Noble, Adaptimmune’s Chief Executive Officer. “Their insights and guidance will be invaluable as we continue to move our pipeline of affinity optimized T-cell therapies forward.”

The inaugural members of Adaptimmune’s scientific advisory board are:

  • Crystal Mackall, M.D., Chair, Adaptimmune Scientific Advisory Board ; Professor of Pediatrics and Medicine; Associate Director of the Stanford Cancer Institute
  • Nabil Ahmed, M.D. , Associate Professor, Department of Pediatrics, Texas Children's Hospital, Texas Children’s Cancer Center; Center for Cell and Gene Therapy, Houston Methodist Hospital, Baylor College of Medicine
  • Michael Dustin, Ph.D. , Professor of Immunology and Wellcome Principal Research Fellow, Director of Research of the Kennedy Institute
  • Keith Flaherty, M.D. , Professor, Medicine, Harvard Medical School; Director of Termeer Center for Target Therapy, Cancer Center, Massachusetts General Hospital 
  • Wolf Fridman, M.D., Ph.D. , Professor Emeritus of Immunology, Paris Descartes University Medical School, Paris, France; President, Canceropole Ile de France
  • Thomas Gajewski, M.D., Ph.D. , Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine - Section of Hematology/Oncology, University of Chicago Medical Center
  • Stephan Grupp, M.D., Ph.D. , Novotny Professor of Pediatrics, University of Pennsylvania Perelman School of Medicine; Director, Cancer Immunotherapy Frontier Program; Director of Translational Research, Children’s Hospital of Philadelphia
  • Arlene Sharpe, M.D., Ph.D. , Fabyan Professor of Comparative Pathology, Microbiology and Immunobiology, Harvard Medical School; Vice Chair for Education, Pathology, Harvard Medical School; Co-Director, Harvard Institute of Translation Immunology (HITI), Harvard Medical School
  • Mario Sznol, M.D. , Professor, Internal Medicine; Leader, Disease-Related Research Team, Melanoma and Renal cell Carcinoma; Vice-Chief, Medical Oncology; Co-Director, Yale Skin SPORE, Yale Cancer Center  

About Adaptimmune Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts Will Roberts Vice President, Investor Relations T:  (215) 825-9306  E: will.roberts@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 38

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 60

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 208

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 17

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading

Top 5 Most Recently Viewed Articles

INTCO Medical Surges Ahead with 40.6% Revenue Boost

Updated Category News Views 94

Eying Growth: INTCO Medical's Impressive Revenue Surge In today's corporate world, a 40.6% revenue jump over a single half-year isn't something to sneeze at. INTCO Medical, a heavyweight in the disposable glove industry, has done exactly that. The whispers out of Zibo, China, hint at a company that’s firing on all cylinders with $1.03 billion in their pockets for the...

Continue Reading
Taylor Davis Joins Pivot Point Consulting to Boost Client Success

Updated Category News Views 108

Pivot Point Consulting brought in a big player back then: Taylor Davis, the former President of KLAS Research. He wasn't just some guy; he founded the KLAS Arch Collaborative. This move was about shaking things up in healthcare consulting during tough times. Desks were buzzing over this power shift. In his past gig at KLAS, Davis was instrumental in creating standards...

Continue Reading
Entegris' Financial Highlights and Outlook for 2025

Updated Category News Views 971

Entegris Reports Strong Fourth Quarter Performance Entegris, Inc. (NASDAQ: ENTG) has recently released its financial results marking a robust conclusion to the fiscal year. The company's fourth-quarter performance surpassed projections for both revenue and non-GAAP earnings per share. CEO Insights on Market Dynamics Bertrand Loy, the President and CEO of Entegris,...

Continue Reading
Top Dividend Stocks Insiders Increased Their Investments In January

Updated Category News Views 109

Insider Purchasing Trends in Dividend Stocks January unveiled strong insider buying activity across various dividend-paying stocks, pointing to confidence in future growth. Leaders in this buying spree were notable companies including Lakeland Industries (NASDAQ: LAKE), York Water (NASDAQ: YORW), and RLI Corp (NYSE: RLI). Such movements may indicate these stocks are worth...

Continue Reading
FDA Approves Omvoh for Crohn's Disease: A New Era in Treatment

Updated Category News Views 515

FDA Approves Omvoh for Crohn's Disease Eli Lilly and Company (NYSE: LLY) proudly announces the FDA's approval of Omvoh (mirikizumab-mrkz), a groundbreaking treatment for adults suffering from moderately to severely active Crohn's disease. This marks a significant advancement, as Omvoh is now recognized for treating not just this debilitating condition but also ulcerative...

Continue Reading